Lilly's tirzepatide superior to semaglutide in
head-to-head trial showing
an average weight loss of
20.2% vs. 13.7%
(INDIANAPOLIS) - Eli Lilly and Company
(NYSE: LLY) announces
topline results from the
SURMOUNT-5 phase 3b
open-label randomized
clinical trial. Tirzepatide
provided a 47% greater
relative weight loss
compared to semaglutide. On
average, tirzepatide led to
a superior weight loss of
20.2% compared to 13.7% with
semaglutide.i At 72 weeks,
tirzepatide beat semaglutide
on both the primary endpoint
and all five key secondary
endpoints in this trial of
adults living with obesity
or overweight with at least
one weight-related medical
problem and without
diabetes.
"Given the
increased interest around
obesity medications, we
conducted this study to help
health care providers and
patients make informed
decisions about treatment
choice," said Leonard C.
Glass, MD, FACE, senior vice
president of global medical
affairs at Lilly
Cardiometabolic Health. "We
are thrilled that today's
findings showed the superior
weight loss of tirzepatide,
which helped patients
achieve 47% more relative
weight loss compared to
semaglutide. Tirzepatide is
in a class of its own as the
only FDA-approved dual GIP
and GLP-1 receptor agonist
obesity medication, and it's
changing how millions of
people manage this chronic
disease."
In
addition, in a key secondary
endpoint, 31.6% of people
taking tirzepatide achieved
at least 25% body weight
loss compared to 16.1% of
those taking semaglutide.
The overall safety
profile of tirzepatide in
SURMOUNT-5 was similar to
previously reported SURMOUNT
trials. The most
reported adverse events in
SURMOUNT-5 for both
tirzepatide and semaglutide
were
gastrointestinal-related and
were generally mild to
moderate in severity.
Lilly will continue to
evaluate the SURMOUNT-5
results, which will be
published in a peer-reviewed
journal and presented at a
medical meeting next year.
About
SURMOUNT-5
SURMOUNT-5 (NCT05822830) was
a multi-center, randomized,
open-label, phase 3b trial
evaluating the efficacy and
safety of tirzepatide
compared with semaglutide in
adults with obesity, or
overweight with at least one
of the following
comorbidities: hypertension,
dyslipidemia, obstructive
sleep apnea (OSA) or
cardiovascular disease, who
did not have diabetes. The
trial randomized 751
participants across the U.S.
and Puerto Rico in a 1:1
ratio to receive maximum
tolerated dose of
tirzepatide (10 mg or 15 mg)
or semaglutide (1.7 mg or
2.4 mg). The primary
objective of the study was
to demonstrate tirzepatide
superiority in percent
change from baseline in body
weight at 72 weeks compared
to semaglutide.
Note: The above
information is intended for
healthcare professionals and
education purposes and is
not meant to influence
prescribing practices or
promote one product over
another nor is it a
substitute for professional
medical advice. Consult with
a healthcare professional
for personalized treatment
options.
